[RGEN] Repligen Corporation Thesis 2026: Bioprocessing Consumables Drive Filtration Chromatography Cyclical Recovery

Key Takeaways

• RGEN FY2025 revenue ~$0.65-0.75B (+5-15% YoY) with adj. EPS ~$1.50-1.95 reflecting continued ~$0.28-0.34B aggregate Filtration + ~$0.18-0.22B aggregate Chromatography + ~$0.10-0.14B aggregate Process Analytics + ~$0.08-0.12B aggregate Proteins + selected various aggregate Fluid Management revenue mix + selected various aggregate post-2024-2025 bioprocessing cyclical recovery under continued President + CEO Olivier Loeillot since 2024 (~1-2 year tenure as Repligen CEO; selected post-2024 succession from Tony Hunt retirement after ~9-year tenure 2015-2024; selected post-2024 succession from Sartorius bioprocess executive + GE Healthcare Life Sciences background + selected primary architect of post-2024 strategic continuity + organic growth focus + portfolio optimization + selected various aggregate post-2024 cost discipline).
• Filtration + Chromatography Bioprocessing Consumables Pipeline (~$0.46-0.56B Revenue): ~$0.28-0.34B aggregate Filtration revenue + ~$0.18-0.22B aggregate Chromatography revenue (aggregate ~70-74% revenue mix); selected primary Filtration (selected primary tangential flow filtration (TFF) + single-use flat sheet cassettes + hollow fiber + selected various aggregate XCell ATF cell retention + selected various aggregate ~consumables-heavy recurring revenue + selected various aggregate ~$0.28-0.34B aggregate Filtration revenue) + selected various aggregate Chromatography (selected primary OPUS pre-packed chromatography columns + selected various aggregate ~ready-to-use single-use chromatography + selected various aggregate ~$0.18-0.22B aggregate Chromatography revenue + selected various aggregate ~consumables-heavy recurring revenue) + selected various aggregate ~biopharma monoclonal antibody (mAb) + cell & gene therapy + vaccine + bispecific + ADC + selected various aggregate ~80%+ aggregate consumables/recurring revenue mix + selected various aggregate post-2024-2025 bioprocessing cyclical recovery (selected primary post-2022-2024 biopharma + CDMO customer inventory destocking + capex normalization + selected various aggregate FY2025-FY2026 cyclical recovery + selected various aggregate ~mAb commercial + clinical pipeline demand).
• Process Analytics + Proteins + Fluid Management Pipeline (~$0.18-0.24B Revenue + Strategic Catalyst): ~$0.10-0.14B aggregate Process Analytics revenue + ~$0.08-0.12B aggregate Proteins revenue + selected various aggregate Fluid Management revenue (aggregate ~26-30% revenue mix); selected primary Process Analytics (selected primary at-line + in-line process analytical technology (PAT) + selected various aggregate FlowVPX + SoloVPE variable pathlength spectroscopy + selected various aggregate ~real-time bioprocess monitoring + selected various aggregate ~$0.10-0.14B aggregate Process Analytics revenue) + selected various aggregate Proteins (selected primary Protein A ligands + selected various aggregate ~OEM ligand supply to chromatography resin manufacturers — Cytiva + Purolite + selected various aggregate + selected various aggregate ~$0.08-0.12B aggregate Proteins revenue + selected various aggregate ~mAb purification ligand demand) + selected various aggregate Fluid Management (selected primary single-use assemblies + tubing + connectors + selected various aggregate ~fluid handling) + selected various aggregate post-2024-2025 Process Analytics + Proteins + Fluid Management organic growth + cross-sell.
• Capital position + balance sheet: ~$0.00 aggregate annual dividend (no regular dividend; selected primary capital reinvestment + organic growth + tuck-in M&A priority); no aggregate FY2025 buybacks; aggregate cash + investments ~$0.7-1.0B; selected primary net cash position (net debt negative; ~$0.5-0.8B aggregate convertible notes); ~$0+ aggregate net leverage (net cash); non-rated to investment-grade credit profile; ~57-60M aggregate diluted shares.
• FY2026 thesis catalysts: Filtration + Chromatography Bioprocessing Consumables pipeline (~$0.46-0.56B + TFF single-use cassettes + XCell ATF + OPUS pre-packed columns + 80%+ consumables/recurring revenue mix + biopharma mAb + cell & gene therapy + vaccine + post-2024-2025 bioprocessing cyclical recovery) + Process Analytics + Proteins + Fluid Management pipeline ($0.18-0.24B + FlowVPX + SoloVPE variable pathlength spectroscopy + Protein A ligands OEM supply + single-use assemblies + organic growth + cross-sell) + ~$0.7-1.0B aggregate cash + investments + net cash balance sheet + Olivier Loeillot organic growth focus + bioprocessing cyclical recovery execution.

Company Background

Repligen Corporation (NASDAQ: RGEN) is a US bioprocessing technology company, founded 1981 in Waltham Massachusetts (~44-year heritage; selected primary post-1981 founding as biopharmaceutical R&D company + selected post-2012-2025 strategic pivot toward bioprocessing technology — chromatography + filtration + process analytics + proteins via acquisitions + selected post-1992 NASDAQ listing). Selected post-1992 NASDAQ listing; selected post-2012-2025 selected various aggregate ~$2B+ aggregate cumulative M&A platform (selected various aggregate Novozymes Biopharma Sweden 2011 + Atoll 2016 + Spectrum 2017 + C Technologies 2019 + ARTeSYN Biosolutions 2021 + Avitide 2021 + Polymem 2022 + Metenova 2023 + selected various aggregate bioprocessing technology acquisitions); selected post-2024 Olivier Loeillot CEO appointment (selected post-2024 succession from Tony Hunt retirement after ~9-year tenure 2015-2024; selected post-2024 ex-Sartorius bioprocess executive + GE Healthcare Life Sciences background); selected post-2024-2025 selected various aggregate organic growth focus + portfolio optimization + cost discipline; HQ Waltham Massachusetts; ~2,500-3,000 employees globally.

RGEN operates as 1 primary segment (bioprocessing technology) with 5 product franchises: Filtration (~40-45% revenue mix; ~$0.28-0.34B; TFF single-use cassettes + hollow fiber + XCell ATF) + Chromatography (~26-30% revenue mix; ~$0.18-0.22B; OPUS pre-packed columns + single-use chromatography) + Process Analytics (~14-18% revenue mix; ~$0.10-0.14B; FlowVPX + SoloVPE variable pathlength spectroscopy) + Proteins (~11-15% revenue mix; ~$0.08-0.12B; Protein A ligands OEM supply) + Fluid Management (~5-8% revenue mix; single-use assemblies + tubing + connectors). End-markets: biopharma monoclonal antibody (mAb) + cell & gene therapy + vaccine + bispecific + ADC + CDMO. Geographic mix: Americas ~45-50% + EMEA ~30-35% + Asia Pacific ~20-25%. Consumables/recurring revenue mix: ~80%+ aggregate.

Capital position: ~$0.00 aggregate annual dividend (no regular dividend; capital reinvestment + organic growth + tuck-in M&A priority); no aggregate FY2025 buybacks; aggregate cash + investments ~$0.7-1.0B; net cash position; ~$0+ aggregate net leverage; non-rated to investment-grade credit profile; ~57-60M aggregate diluted shares.

Filtration + Chromatography Bioprocessing Consumables Pipeline (~$0.46-0.56B Revenue)

The Filtration + Chromatography Bioprocessing Consumables pipeline is RGEN's foundation thesis: ~$0.28-0.34B aggregate Filtration revenue + ~$0.18-0.22B aggregate Chromatography revenue (aggregate ~70-74% revenue mix); selected primary Filtration (selected primary tangential flow filtration (TFF) + single-use flat sheet cassettes + hollow fiber + selected various aggregate XCell ATF cell retention + selected various aggregate ~consumables-heavy recurring revenue + selected various aggregate ~$0.28-0.34B aggregate Filtration revenue) + selected various aggregate Chromatography (selected primary OPUS pre-packed chromatography columns + selected various aggregate ~ready-to-use single-use chromatography + selected various aggregate ~$0.18-0.22B aggregate Chromatography revenue + selected various aggregate ~consumables-heavy recurring revenue) + selected various aggregate ~biopharma monoclonal antibody (mAb) + cell & gene therapy + vaccine + bispecific + ADC + selected various aggregate ~80%+ aggregate consumables/recurring revenue mix + selected various aggregate post-2024-2025 bioprocessing cyclical recovery (selected primary post-2022-2024 biopharma + CDMO customer inventory destocking + capex normalization + selected various aggregate FY2025-FY2026 cyclical recovery + selected various aggregate ~mAb commercial + clinical pipeline demand).

FY2025 Filtration + Chromatography Bioprocessing Consumables dynamics ($0.46-0.56B aggregate revenue): selected continued post-2024 ~+5-15% aggregate Filtration + Chromatography revenue growth (selected primary post-2022-2024 biopharma + CDMO customer inventory destocking + capex normalization recovery + selected various aggregate ~mAb commercial + clinical pipeline demand + selected various aggregate cell & gene therapy + vaccine demand + selected various aggregate ~80%+ aggregate consumables/recurring revenue mix + selected various aggregate TFF single-use cassettes + XCell ATF + OPUS pre-packed columns) + ~$0.28-0.34B aggregate Filtration revenue + selected various aggregate ~$0.18-0.22B aggregate Chromatography revenue + selected various aggregate ~30-35% aggregate Filtration + Chromatography adj. operating margin. Selected post-2024 ~$1.10-1.50 incremental annual EPS contribution as Filtration + Chromatography Bioprocessing Consumables pipeline drives incremental recurring consumables margin recovery.

FY2026 catalyst: continued Filtration + Chromatography Bioprocessing Consumables pipeline + ~$1.10-1.50 incremental annual EPS contribution under continued Olivier Loeillot leadership (~1-2 year tenure). Selected aggregate ~$0.48-0.62B aggregate FY2026 combined Filtration + Chromatography revenue + selected various ~+8-18% aggregate growth + selected various aggregate ~80%+ aggregate consumables/recurring revenue mix + selected various aggregate post-2024-2025 bioprocessing cyclical recovery continuation + selected various aggregate ~mAb commercial + clinical pipeline demand + selected various aggregate cell & gene therapy + vaccine demand + selected various aggregate TFF single-use cassettes + XCell ATF + OPUS pre-packed columns + selected various aggregate ~30-37% aggregate Filtration + Chromatography adj. operating margin (improvement; cyclical recovery operating leverage + cost discipline). Risks: Sartorius (Germany; FRA SRT; bioprocess — TFF + filtration + single-use leader) + Danaher / Cytiva (chromatography resins + filtration + single-use — bioprocess leader) + Thermo Fisher Scientific (TMO, ~$160-200B Mcap; bioprocess + single-use) + Merck KGaA / MilliporeSigma (Germany; FRA MRK; bioprocess + filtration + single-use) + Pall Corporation / Danaher (filtration) + Donaldson Company (DCI, ~$8-10B; Life Sciences filtration) + Entegris (ENTG, ~$15-20B; bioprocess + microcontamination) + W. L. Gore (private; filtration membranes) + selected various aggregate bioprocessing technology + filtration + chromatography competitive considerations + biopharma + CDMO customer inventory destocking + restocking + capex cycle considerations + biopharma R&D funding cycle considerations + mAb + cell & gene therapy + vaccine pipeline cycle considerations + selected various aggregate single-use vs stainless steel bioprocessing considerations + selected various aggregate biosimilar + China biopharma considerations.

Process Analytics + Proteins + Fluid Management Pipeline (~$0.18-0.24B Revenue + Strategic Catalyst)

The Process Analytics + Proteins + Fluid Management pipeline is RGEN's primary growth thesis: ~$0.10-0.14B aggregate Process Analytics revenue + ~$0.08-0.12B aggregate Proteins revenue + selected various aggregate Fluid Management revenue (aggregate ~26-30% revenue mix); selected primary Process Analytics (selected primary at-line + in-line process analytical technology (PAT) + selected various aggregate FlowVPX + SoloVPE variable pathlength spectroscopy + selected various aggregate ~real-time bioprocess monitoring + selected various aggregate ~$0.10-0.14B aggregate Process Analytics revenue) + selected various aggregate Proteins (selected primary Protein A ligands + selected various aggregate ~OEM ligand supply to chromatography resin manufacturers — Cytiva + Purolite + selected various aggregate + selected various aggregate ~$0.08-0.12B aggregate Proteins revenue + selected various aggregate ~mAb purification ligand demand) + selected various aggregate Fluid Management (selected primary single-use assemblies + tubing + connectors + selected various aggregate ~fluid handling) + selected various aggregate post-2024-2025 Process Analytics + Proteins + Fluid Management organic growth + cross-sell.

FY2025 Process Analytics + Proteins + Fluid Management dynamics: selected primary ~$0.10-0.14B aggregate Process Analytics revenue + selected various aggregate FlowVPX + SoloVPE variable pathlength spectroscopy + ~real-time bioprocess monitoring + selected various aggregate ~$0.08-0.12B aggregate Proteins revenue + selected various aggregate Protein A ligands + ~OEM ligand supply to chromatography resin manufacturers (Cytiva + Purolite + selected various aggregate) + ~mAb purification ligand demand + selected various aggregate Fluid Management single-use assemblies + tubing + connectors + selected various aggregate post-2024-2025 Process Analytics + Proteins + Fluid Management organic growth + cross-sell + selected various aggregate ~25-35% aggregate Process Analytics + Proteins + Fluid Management adj. operating margin. Selected post-2024 ~$0.40-0.55 incremental annual EPS contribution as Process Analytics + Proteins + Fluid Management pipeline drives incremental margin.

FY2026 catalyst: continued Process Analytics + Proteins + Fluid Management pipeline + ~$0.40-0.55 incremental EPS contribution. Selected aggregate ~$0.19-0.26B aggregate FY2026 combined Process Analytics + Proteins + Fluid Management revenue + selected various aggregate ~+8-18% aggregate growth + selected various aggregate FlowVPX + SoloVPE variable pathlength spectroscopy + ~real-time bioprocess monitoring + Process Analytical Technology (PAT) adoption + selected various aggregate Protein A ligands OEM supply + ~mAb purification ligand demand + selected various aggregate Fluid Management single-use assemblies + tubing + connectors + selected various aggregate post-2024-2025 organic growth + cross-sell + selected various aggregate ~25-37% aggregate adj. operating margin. Risks: Sartorius + Danaher/Cytiva + Thermo Fisher Scientific + Merck KGaA/MilliporeSigma + Pall/Danaher + Entegris + Bruker (BRKR, ~$6-9B Mcap; process analytics + spectroscopy) + Agilent Technologies (A, ~$30-40B; analytical instruments) + Mettler-Toledo (MTD, ~$25-30B; process analytics + weighing) + Purolite/Ecolab (chromatography resins — Protein A ligand customer) + selected various aggregate process analytics + Protein A ligand + fluid management competitive considerations + Process Analytical Technology (PAT) adoption cycle considerations + biopharma + CDMO customer inventory destocking + restocking + capex cycle considerations + chromatography resin manufacturer demand considerations (Cytiva + Purolite Protein A ligand customers) + selected various aggregate single-use bioprocessing adoption considerations + selected various aggregate organic growth + cross-sell execution considerations.

Capital Position + Balance Sheet

Capital position + balance sheet: ~$0.00 aggregate annual dividend (no regular dividend; selected primary capital reinvestment + organic growth + tuck-in M&A priority) + no aggregate FY2025 buybacks + aggregate cash + investments ~$0.7-1.0B + selected primary net cash position (net debt negative; ~$0.5-0.8B aggregate convertible notes) + ~$0+ aggregate net leverage (net cash) + non-rated to investment-grade credit profile + ~57-60M aggregate diluted shares + weighted average debt maturity ~3-5 years.

FY2026 catalyst: continued no dividend + no buyback policy + selected continued ~$0.7-1.0B aggregate cash + investments (selected primary net cash position) + selected various aggregate ~$0+ aggregate tuck-in M&A capacity (selected primary bioprocessing technology bolt-on acquisitions) + selected various aggregate convertible notes refinancing/repurchase considerations + selected continued non-rated to investment-grade credit profile. Selected no dividend policy + selected net cash balance sheet + selected ~$0.7-1.0B aggregate cash + investments support continued Filtration + Chromatography + Process Analytics + Proteins + Fluid Management organic growth + R&D investment + bioprocessing technology tuck-in M&A.

Key Core Metrics

• FY2025 revenue ~$0.65-0.75B (+5-15% YoY) vs $0.64B FY2024; adj. EPS ~$1.50-1.95
• 1 primary segment: bioprocessing technology ~100% (5 product franchises)
• Product franchises: Filtration ~40-45% ($0.28-0.34B; TFF single-use cassettes + hollow fiber + XCell ATF) + Chromatography ~26-30% ($0.18-0.22B; OPUS pre-packed columns + single-use chromatography) + Process Analytics ~14-18% ($0.10-0.14B; FlowVPX + SoloVPE variable pathlength spectroscopy) + Proteins ~11-15% ($0.08-0.12B; Protein A ligands OEM supply) + Fluid Management ~5-8% (single-use assemblies + tubing + connectors)
• End-markets: biopharma monoclonal antibody (mAb) + cell & gene therapy + vaccine + bispecific + ADC + CDMO
• Geographic mix: Americas ~45-50% + EMEA ~30-35% + Asia Pacific ~20-25%
• Consumables/recurring revenue mix: ~80%+ aggregate
• Filtration + Chromatography adj. operating margin: ~30-35% aggregate
• post-2024-2025 bioprocessing cyclical recovery (post-2022-2024 biopharma + CDMO customer inventory destocking + capex normalization)
• post-2012-2025 M&A platform: Novozymes Biopharma 2011 + Atoll 2016 + Spectrum 2017 + C Technologies 2019 + ARTeSYN 2021 + Avitide 2021 + Polymem 2022 + Metenova 2023
• Aggregate adj. EBITDA: ~$0.15-0.22B FY2025
• Net cash position (net debt negative); ~$0.5-0.8B aggregate convertible notes
• ~$0+ aggregate net leverage (net cash)
• ~57-60M aggregate diluted shares; ~$0 total capital return FY2025 (no dividend; no buyback)
• No dividend; no buyback (capital reinvestment + organic growth + tuck-in M&A priority)
• Non-rated to investment-grade credit profile
• ~2,500-3,000 employees globally
• Olivier Loeillot CEO since 2024 (~1-2 year tenure; ex-Sartorius bioprocess executive + GE Healthcare Life Sciences)
• HQ Waltham Massachusetts; founded 1981

Market Evaluation

RGEN FY2026 market evaluation: at ~$100-180 share price + ~57-60M aggregate diluted shares = ~$6-11B market cap; no dividend + no buyback. Selected primary RGEN peers: Sartorius (Germany; FRA SRT; bioprocess — TFF + filtration + single-use leader) + Danaher / Cytiva (chromatography resins + filtration + single-use — bioprocess leader) + Thermo Fisher Scientific (TMO, ~$160-200B Mcap; bioprocess + single-use) + Merck KGaA / MilliporeSigma (Germany; FRA MRK; bioprocess + filtration + single-use) + Donaldson Company (DCI, ~$8-10B; Life Sciences filtration) + Entegris (ENTG, ~$15-20B; bioprocess + microcontamination) + Bio-Techne (TECH, ~$8-12B; reagents + proteins) + Bruker (BRKR, ~$6-9B; process analytics + spectroscopy) + Mettler-Toledo (MTD, ~$25-30B; process analytics) + Avantor (AVTR, ~$10-15B; bioprocess + lab supplies) + West Pharmaceutical Services (WST, ~$25-30B; pharma packaging + delivery) + selected various aggregate bioprocessing technology + life science tools companies. Selected RGEN ~30-50x P/E (bioprocessing technology with Filtration + Chromatography consumables + Process Analytics + Proteins + Fluid Management + ~80%+ consumables/recurring revenue mix + biopharma mAb + cell & gene therapy + vaccine + post-2024-2025 bioprocessing cyclical recovery + net cash balance sheet + tuck-in M&A optionality) + selected ~8-15x P/Sales + selected ~25-40x EV/EBITDA + no dividend + selected aggregate ~$0.70-0.85B aggregate FY2026 revenue + selected aggregate ~$1.90-2.50 aggregate FY2026 EPS + net cash balance sheet + selected aggregate Filtration + Chromatography Bioprocessing Consumables + Process Analytics + Proteins + Fluid Management pipeline. FY2026 base case: ~$0.70-0.85B aggregate revenue + ~$1.90-2.50 adj. EPS + net cash balance sheet. Bull case: Filtration + Chromatography Bioprocessing Consumables pipeline acceleration (post-2024-2025 bioprocessing cyclical recovery continuation + ~mAb commercial + clinical pipeline demand + cell & gene therapy + vaccine demand + ~80%+ consumables/recurring revenue mix + TFF single-use cassettes + XCell ATF + OPUS pre-packed columns + ~30-37% Filtration + Chromatography adj. operating margin cyclical recovery operating leverage) + Process Analytics + Proteins + Fluid Management pipeline acceleration (FlowVPX + SoloVPE variable pathlength spectroscopy + Process Analytical Technology adoption + Protein A ligands OEM supply + Fluid Management single-use assemblies + organic growth + cross-sell) + tuck-in M&A drives ~$0.78-0.95B aggregate revenue + ~$2.40-3.10 EPS. Bear case: Sartorius + Danaher/Cytiva + Thermo Fisher + Merck KGaA/MilliporeSigma + Pall/Danaher + Entegris + Bruker + Mettler-Toledo competitive intensification + biopharma + CDMO customer inventory destocking + restocking + capex cycle considerations + biopharma R&D funding cycle considerations + mAb + cell & gene therapy + vaccine pipeline cycle considerations + single-use vs stainless steel bioprocessing considerations + biosimilar + China biopharma considerations + Process Analytical Technology (PAT) adoption cycle considerations + chromatography resin manufacturer demand considerations (Cytiva + Purolite Protein A ligand customers) + organic growth + cross-sell execution considerations + post-2024 Olivier Loeillot CEO succession planning considerations (~1-2 year tenure) drives ~$0.62-0.72B revenue + ~$1.40-1.90 EPS. The thesis depends on Filtration + Chromatography Bioprocessing Consumables + Process Analytics + Proteins + Fluid Management + ~80%+ consumables/recurring revenue mix + biopharma mAb + cell & gene therapy + vaccine + post-2024-2025 bioprocessing cyclical recovery + net cash balance sheet + tuck-in M&A + Olivier Loeillot organic growth focus + bioprocessing cyclical recovery execution.